Indivior said new real-world data show that adherence to its monthly injectable Buprenorphine, SUBLOCADE, significantly reduces relapse risk and lowers healthcare utilization in opioid use disorder patients. The findings support the product's clinical value and could modestly improve physician adoption and payer confidence. The release is positive for Indivior but does not include financial results or new guidance.
Indivior said new real-world data show that adherence to its monthly injectable Buprenorphine, SUBLOCADE, significantly reduces relapse risk and lowers healthcare utilization in opioid use disorder patients. The findings support the product's clinical value and could modestly improve physician adoption and payer confidence. The release is positive for Indivior but does not include financial results or new guidance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
